Literature DB >> 21655930

Choosing a treatment for patients at the time a fracture is presented.

S Bobo Tanner1.   

Abstract

The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21655930     DOI： 10.1007/s11914-011-0061-4

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


  44 in total

1.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Authors:  Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

2.  What predicts initiation of osteoporosis treatment after fractures: education organisation or patients' characteristics?

Authors:  Luca Semerano; Xavier Guillot; Maurizio Rossini; Evelyne Avice; Thierry Bégué; Mathias Wargon; Marie-Christophe Boissier; Nathalie Saidenberg-Kermanac'h
Journal:  Clin Exp Rheumatol       Date:  2011-02-23       Impact factor: 4.473

3.  Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.

Authors:  Negin Amanat; Michelle McDonald; Craig Godfrey; Lynne Bilston; David Little
Journal:  J Bone Miner Res       Date:  2007-06       Impact factor: 6.741

4.  Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

Authors:  E Van Beek; C Löwik; I Que; S Papapoulos
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

5.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

6.  Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.

Authors:  Stephen J Gomberg; Rosanna L Wustrack; Nicola Napoli; Claude D Arnaud; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2011-03-23       Impact factor: 5.958

7.  Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.

Authors:  Anke J Roelofs; Philippa A Hulley; Annemieke Meijer; Frank H Ebetino; R Graham G Russell; Claire M Shipman
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

Review 8.  Gender differences in health care expenditures, resource utilization, and quality of care.

Authors:  Gary M Owens
Journal:  J Manag Care Pharm       Date:  2008-04

9.  Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Authors:  Louis C Gerstenfeld; Daniel J Sacks; Megan Pelis; Zachary D Mason; Dana T Graves; Mauricio Barrero; Michael S Ominsky; Paul J Kostenuik; Elise F Morgan; Thomas A Einhorn
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741

10.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507
View more
  1 in total

1.  Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair.

Authors:  M Saito; S N Moore-Lotridge; S Uppuganti; S Egawa; T Yoshii; J P Robinette; S L Posey; B H Y Gibson; H A Cole; G D Hawley; S A Guelcher; S B Tanner; J R McCarthy; J S Nyman; J G Schoenecker
Journal:  Osteoporos Int       Date:  2021-10-31       Impact factor: 5.071
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.